A NOVEL NUCLEAR COUNTERMEASURE TARGETING ENDOTHELIAL CELLS AND STEM CELLSTO COMBAT ARS AND DELAYED MULTIPLE ORGAN DYSFUNCTION

蚕蛹生物治疗公司正在率先使用天然多肽再生信号来恢复正常干细胞群体，以防止损伤、缺血和辐射造成的长期损害。在这份合同中，他们将进一步开发他们的产品TP508，这是一种凝血酶多肽，通过在建立的急性辐射和延迟辐射效应的小鼠和猪模型中获得疗效数据、病理生理和药物计量数据，以支持Animal Rule IND并获得许可，并在该项目结束时启动关键的动物研究。TP508是一种用途改变的产品，已经在人体皮肤和肌肉骨骼修复的临床试验中使用。

Chrysalis Biotherapeutics, Inc. is pioneering the use of natural peptide regenerative signals that restore normal stem cell populations to prevent long-term damage from injury, ischemia, and radiation. In this contract they will further develop their product, TP508, a thrombin peptide by obtaining efficacy data, pathophysiological and pharmacometric data in established murine and porcine models of acute and delayed effects of acute radiation to support Animal Rule IND and licensure and initiate pivotal animal studies at the end of this project. TP508 is a repurposed product already in human clinical trials for dermal and musculoskeletal repair.